NAMS Stock Analysis: Buy, Sell, or Hold?
NAMS - NewAmsterdam Pharma Company N.V. Ordinary Shares
$27.87
0.09 (0.32%)
▲
5d:
+3.3%
30d:
-8.77%
90d:
-22.02%
BUY
HIGH Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 05, 2026
0d
Smart Money Distribution
Options positioning is turning defensive after a sharp run-up - a pattern consistent with institutional profit-taking. View Scanner →
Signal fired Aug 10, 2026 at $27.98 · last confirmed Aug 17, 2026
Strength: 3.6/10
Get Alerted When NAMS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: NAMS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: NAMS shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: NAMS is currently trading at $27.87, which is considered slightly low relative to its 30-day fair value range of $27.05 to $30.42.
Technical Outlook: Technically, NAMS is in a downtrend. Immediate support is located at $26.01, while resistance sits at $28.97.
Market Sentiment: NAMS scores 82/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $52.01 (+86.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, NAMS is in a downtrend. Immediate support is located at $26.01, while resistance sits at $28.97.
Market Sentiment: NAMS scores 82/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. In the options market, Implied Volatility is low (27th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $52.01 (+86.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$27.05 -
$30.42
Company Quality Score
60/100
(HOLD)
Options IV Signal
27th percentile
(LOW)
Volume Confirmation
HIGH
Confidence Score
95.8%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Options cheap (IV 27th percentile)
- BULLISH: Strong technical setup (82/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 86.6% below Wall St target ($52.01)
- BULLISH: Bottoming setup score 82/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$27.05 -
$30.42
Current vs Trading Range
SLIGHTLY LOW
Expected Move (7 Days)
±$3.64
(13.0%)
Support & Resistance Levels
Support Level
$26.01
Resistance Level
$28.97
Current Trend
Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.18
Wall Street Target
$52.01
(+86.6%)
Revenue Growth (YoY)
-80.7%
Share & Embed Analysis
Last updated: August 23, 2026 3:03 AM ET
Data refreshes hourly during market hours. Next update: 4:03 AM
Data refreshes hourly during market hours. Next update: 4:03 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is NAMS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
8
Sells
Net
INSIDERS SELLING
Recent Transactions
Louis G Lange
SELL
44619 shares
2026-03-11
Johannes Jacob Piete Kas…
SELL
101409 shares
2026-03-09
Johannes Jacob Piete Kas…
SELL
94124 shares
2026-03-06
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$125 | 41 HOLD |
Advanced NAMS Option Strategies
Professional options setups generated by AI based on today's NAMS price and gamma walls.
